Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
-- Patients to Receive Single-administration of Gene Therapy Candidate ADVM-043 -- -- Company Expects to Report Preliminary Data in the Second Half of 2018 -- MENLO PARK, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM …